专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20230139671A1 OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS 有权
公开(公告)号：US20230139671A1
公开(公告)日：2023-05-04
申请号：US17815877
申请日：2022-07-28
申请人： Selecta Biosciences, Inc.
发明人： David H. Altreuter , Aaron P. Griset
IPC分类号： A61K9/00 , A61K9/51 , A61K9/19 , C12N15/88
摘要： This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.

2. 发明申请

US20230138946A1 Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) 有权
公开(公告)号：US20230138946A1
公开(公告)日：2023-05-04
申请号：US17878998
申请日：2022-08-02
申请人： Ovation Science Inc.
发明人： James A. Roszell
IPC分类号： A61K9/00 , A61K31/352 , A61K31/05 , A61K47/32 , A61K47/06
摘要： A transdermal delivery composition for the delivery to skin and the penetration of the skin includes: (a) a therapeutic effective amount of a cannabinoid mixture, wherein the cannabinoid mixture comprises cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) at a weight ratio of about 1:20 to about 20:1; (b) a hydrophilic polymer/hydrophobic polymer adduct in an amount sufficient to hold the cannabinoid composition and provide a sustain release of the cannabinoid mixture after application to skin tissue over a time period of at least 6 hours; (c) a penetrant component in an amount sufficient to assist with a transdermal penetration of the cannabinoid mixture through skin tissue once the composition has been applied to skin tissue; (d) a surfactant component in an amount sufficient to stabilize the polymer adduct and release the cannabinoid mixture from the transdermal delivery composition upon application to skin tissue; and (e) at least about 70 wt. % water. A method of application of a transdermal delivery composition to skin tissue includes applying the transdermal delivery composition to skin tissue and spreading the composition to form a film on the skin tissue. A method for formulating a transdermal delivery composition based on a desired penetration weight ratio of CBD to THC through skin tissue includes selecting a formulation weight ratio of CBD to THC for formulating the composition, wherein the weight ratio is determined by multiplying the desired penetration weight ratio of CBD to THC by a CBD/THC delivery factor, wherein the CBD/THC delivery factor.

3. 发明申请

US20230138361A1 ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS 有权
公开(公告)号：US20230138361A1
公开(公告)日：2023-05-04
申请号：US17835442
申请日：2022-06-08
申请人： AQUESTIVE THERAPEUTICS, INC.
发明人： Alexander Mark Schobel , Stephanie Marie Varjan , Stephen Paul Wargacki
IPC分类号： A61K31/137 , A61K9/00 , A61J1/03 , A61J1/05 , A61J7/00 , A61K9/70 , A61K31/085 , A61K36/61 , A61K47/10 , A61K47/12 , A61K47/22 , A61K47/38
摘要： Pharmaceutical compositions having enhanced active component permeation properties are described.

4. 发明申请

US20230138306A1 ORAL PRODUCT WITH A BASIC AMINE AND AN ION PAIRING AGENT 有权
公开(公告)号：US20230138306A1
公开(公告)日：2023-05-04
申请号：US17955895
申请日：2022-09-29
申请人： NICOVENTURES TRADING LIMITED
发明人： MICHAEL ZAWADZKI , KAI TANG , STEVEN LEE ALDERMAN , THOMAS H. POOLE
IPC分类号： A61K9/00 , A61K31/194 , A61K31/4439 , A61K47/38 , A61K45/06
摘要： The disclosure provides a composition configured for oral use, the composition including at least one filler, water, a basic amine, and an organic acid, an alkali metal salt of an organic acid, or a combination thereof, wherein the organic acid has a logP value of from about 1 to about 12. At least a portion of the basic amine is associated with at least a portion of the organic acid or the alkali metal salt thereof. The association is in the form of a basic amine-organic acid salt, an ion pair between the basic amine and a conjugate base of the organic acid, or a combination of both. The organic acid is a monoester of a dicarboxylic acid or is a carotenoid derivative having one or more carboxylic acids.

5. 发明申请

US20230137434A1 CAR Peptide for Improved Coronavirus Survival 有权
公开(公告)号：US20230137434A1
公开(公告)日：2023-05-04
申请号：US17912312
申请日：2021-03-19
申请人： Vascular Biosciences
发明人： David Mann
IPC分类号： A61K47/64 , A61K31/573 , A61P9/00 , A61P37/06 , A61P31/14 , A61K47/55 , A61K9/127 , A61P29/00 , A61K31/706 , A61K39/395 , A61K49/18 , A61K49/10 , A61K49/14 , A61P3/10 , A61K31/197 , A61K38/36 , A61K38/21 , A61K51/08 , A61K9/00 , A61K38/08
摘要： A conjugate for treating an individual suffering from a disease, wherein the conjugate is comprised of: a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; and at least one therapeutic molecule and methods for making and administering same. Also disclosed is a combination product for use in the treatment of a disease, wherein the combination product comprises: (a) a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; (b) a liposome, wherein the targeting peptide is encapsulated within the liposome; and (c) an effective amount of an anti-inflammatory agent and methods for making and administering same.

6. 发明申请

US20230136824A1 N-N-DIMETHYLTRYPTAMINE (DMT) AND DMT ANALOG COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF 有权
公开(公告)号：US20230136824A1
公开(公告)日：2023-05-04
申请号：US17974443
申请日：2022-10-26
申请人： ATAI Life Sciences AG
发明人： Srinivas G. Rao , Glen Short
IPC分类号： A61K31/4045 , A61K9/70 , A61K9/00 , A61K47/32 , A61K47/38 , A61K47/12 , A61K47/10 , A61K47/42 , A61K47/26
摘要： Pharmaceutical compositions including an amorphous N—N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.

7. 发明申请

US20230136075A1 TREATMENT FOR SEPSIS-INDUCED ORGAN DYSFUNCTION 有权
公开(公告)号：US20230136075A1
公开(公告)日：2023-05-04
申请号：US17995700
申请日：2021-04-08
申请人： Rinaldo Bellomo , The Florey Institute of Neuroscience and Mental Health , Austin Health
发明人： Rinaldo Bellomo , Yugeesh Ryan Lankadeva , Clive Newton May
IPC分类号： A61K31/375 , A61K9/00 , A61P31/00 , A61K47/26
摘要： Provided herein are methods for treating or preventing a condition, and/or symptom or clinical manifestation, associated with systemic infection wherein a subject is intravenously administered ascorbic acid or a pharmaceutically acceptable salt, ester or isomer thereof in an amount of between about 700 mg/kg body weight and about 4,000 mg/kg body weight per day, optionally as a first bolus infusion followed by a subsequent continuous infusion. Also provided are methods comprising intravenously administering to the subject ascorbic acid or a pharmaceutically acceptable salt, ester or isomer thereof: (i) as a bolus dose of from about 350 mg/kg body weight to about 500 mg/kg body weight; and (ii) following (i), by continuous infusion over at least several hours at a dose of from about 60 mg/kg body weight/hr to about 500 mg/kg body weight/hr. Typically, the condition is sepsis or septic shock.

8. 发明申请

US20230135366A1 LIPOIC ACID CHOLINE ESTER COMPOSITIONS AND METHODS TO STABILIZE INTO PHARMACEUTICALLY RELEVANT DRUG PRODUCTS 有权
公开(公告)号：US20230135366A1
公开(公告)日：2023-05-04
申请号：US16335732
申请日：2017-09-22
申请人： NOVARTIS AG
发明人： Shikha BARMAN , Koushik BARMAN , William BURNS , Kathryn CRAWFORD , Anne-Maria CROMWICK , Kevin WARD
IPC分类号： A61K31/385 , A61K47/40 , A61K9/08 , A61K47/18 , A61K9/00
摘要： The present invention describes ophthalmic lipoic acid choline ester compositions and specific processes to produce biocompatible formulations of said compositions suitable for the eye.

9. 发明申请

US20230135227A1 USE OF PHYCOBILIPROTEIN (PBP) TO INHIBIT OR TREAT SARS-COV-2 INFECTION 有权
公开(公告)号：US20230135227A1
公开(公告)日：2023-05-04
申请号：US17914805
申请日：2021-03-25
申请人： Back of the Yards Algae Sciences LLC
发明人： Leonard Lerer
IPC分类号： A61K38/16 , C12N1/12 , A61K9/00
摘要： The present invention relates to the use of phycobiliprotein (PBP) to inhibit or treat SARS-CoV-2 infection and COVID 19.

10. 发明申请

US20230134922A1 TOPICAL DELIVERY OF BUFFERING AGENTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS 有权
公开(公告)号：US20230134922A1
公开(公告)日：2023-05-04
申请号：US17817774
申请日：2022-08-05
申请人： Dyve Biosciences, Inc.
发明人： Ryan BEAL
IPC分类号： A61K33/00 , A61K9/00 , A61K45/06 , A61K31/198 , A61K31/133 , A61K47/14 , A61K47/10 , A61K47/24 , A61K31/704
摘要： Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for increasing resistance to viral infections and improving immune system activity. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for modulating the pH (e.g., raising) of a tissue or microenvironment for the prevention of and treatment of a viral infection and improving the immune response by activating immune cells (e.g., neutrophils, monocytes and macrophages, natural killer cells, dendritic cells, and platelets and endothelial cells).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式